114 related articles for article (PubMed ID: 21820319)
1. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
Nakahigashi M; Yamamoto T
Cytokine; 2011 Nov; 56(2):531-5. PubMed ID: 21820319
[TBL] [Abstract][Full Text] [Related]
2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
3. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
4. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
5. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
6. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L; Laclotte C; Bigard MA
Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
[TBL] [Abstract][Full Text] [Related]
8. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
Baldassano R; Braegger CP; Escher JC; DeWoody K; Hendricks DF; Keenan GF; Winter HS
Am J Gastroenterol; 2003 Apr; 98(4):833-8. PubMed ID: 12738464
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
Reinisch W; Wang Y; Oddens BJ; Link R
Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
[TBL] [Abstract][Full Text] [Related]
10. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
11. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
12. Infliximab therapy in Crohn's disease: a pragmatic approach?
Kevans D; Keegan D; Mulcahy HE; O'Donoghue DP
Aliment Pharmacol Ther; 2006 Jul; 24(2):351-9. PubMed ID: 16842462
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].
Gong JF; Niu LY; Wei XW; Zhu WM; Li N; Li JS
Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(16):1213-7. PubMed ID: 19781164
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.
Vadan R; Gheorghe LS; Constantinescu A; Gheorghe C
Clin Nutr; 2011 Feb; 30(1):86-91. PubMed ID: 20719413
[TBL] [Abstract][Full Text] [Related]
15. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
16. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
17. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
18. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
19. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
[TBL] [Abstract][Full Text] [Related]
20. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
Kane SV; Chao J; Mulani PM
Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
